Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) EBT Margin (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EBT Margin for 16 consecutive years, with 0.57% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 1403.0% to 0.57% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 9.08% through Dec 2025, down 1018.0% year-over-year, with the annual reading at 9.08% for FY2025, 1018.0% down from the prior year.
  • EBT Margin for Q4 2025 was 0.57% at Anika Therapeutics, up from 8.04% in the prior quarter.
  • The five-year high for EBT Margin was 23.93% in Q2 2021, with the low at 788.48% in Q4 2023.
  • Average EBT Margin over 5 years is 74.18%, with a median of 8.16% recorded in 2025.
  • The sharpest move saw EBT Margin tumbled -56793bps in 2022, then surged 80193bps in 2024.
  • Over 5 years, EBT Margin stood at 18.54% in 2021, then plummeted by -3063bps to 586.47% in 2022, then tumbled by -34bps to 788.48% in 2023, then soared by 102bps to 13.45% in 2024, then crashed by -104bps to 0.57% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 0.57%, 8.04%, and 14.05% for Q4 2025, Q3 2025, and Q2 2025 respectively.